Diabetes Mellitus Accelerates Alzheimer′s Disease Development by Affecting the Gut Microbiome.
Increasing evidence suggests a link between Alzheimer′s disease (AD) and diabetes mellitus (DM). However, the precise mechanisms by which DM contributes to AD remain unclear. This study is aimed at elucidating the potential role of DM in the early stages of AD. Accordingly, a streptozotocin (STZ)‐in...
| Published in: | BioMed Research International Vol. 2026; pp. 1 - 12 |
|---|---|
| Main Authors: | , , , , |
| Format: | diagnostic images pictorial research tables/charts Journal Article |
| Published: |
Wiley-Blackwell
3/6/2026
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192158117&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192158117 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 3/6/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 192158117 192158117 192158117 10.1155/bmri/9974079 192158117 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Diabetes Mellitus Accelerates Alzheimer′s Disease Development by Affecting the Gut Microbiome. aug: au: He, Qiong Zhao, Zixiao Jiang, Donglang Fei, Aihua Abhimanyu, Abhimanyu affil: Department of General Medicine,, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,, Shanghai, China, xinhuamed.com.cn sug: subj: Diabetes Mellitus Complications Alzheimer's Disease Physiopathology Alzheimer's Disease Risk Factors Brain Physiopathology Gut Microbiota Metabolism Risk Assessment Animal Studies Models, Biological Mice Amyloid beta-Peptides Metabolism Brain Radiography Brain Metabolism Brain Pathology Butyric Acids Pharmacodynamics Fatty Acids, Volatile Metabolism Gut Microbiota Drug Effects Positron Emission Tomography Computed Tomography Funding Source Immunohistochemistry Epithelium Reverse Transcriptase Polymerase Chain Reaction Fluorescent Antibody Technique Butyric Acids Administration and Dosage Administration, Oral Staining and Labeling Intestinal Barrier Function Sequence Analysis Alzheimer's Disease Microbiology Disease Progression Metabolism Paired T-Tests Unpaired T-Tests One-Way Analysis of Variance Descriptive Statistics Comparative Studies ab: Increasing evidence suggests a link between Alzheimer′s disease (AD) and diabetes mellitus (DM). However, the precise mechanisms by which DM contributes to AD remain unclear. This study is aimed at elucidating the potential role of DM in the early stages of AD. Accordingly, a streptozotocin (STZ)‐induced diabetic 5 × familial AD (FAD) mouse model was established. Immunohistochemistry and positron emission tomography/computed tomography (PET/CT) scanning were performed to examine amyloid beta (Aβ) deposition in the brain. The integrity of the colonic epithelium was assessed using quantitative reverse transcription–polymerase chain reaction (qRT‐PCR) and immunofluorescence staining. Microbial diversity analysis was conducted for 5 × FAD mice with and without STZ‐induced DM to determine shifts in intestinal flora profiles. After oral administration of butyrate to STZ‐treated 5 × FAD mice, we observed that Aβ deposition in the brain was decreased, and the intestinal flora improved. Immunohistochemistry and PET/CT findings revealed a marked increase in Aβ formation in the brains of 5 × FAD mice treated with STZ. qRT‐PCR and immunofluorescence staining revealed severe intestinal barrier dysfunction in these mice. Gut microbiota sequencing indicated significant dysbiosis in STZ‐treated 5 × FAD mice, characterized by a reduction in short‐chain fatty acid (SCFA)–producing species. After oral administration of butyrate, Aβ deposition in the brains of STZ‐treated 5 × FAD mice was significantly reduced, and beneficial changes occurred in the intestinal flora, including increases in bacteria associated with SCFA production and neurological function. Dysregulation of the gut microbiome may exacerbate cerebral amyloidosis during AD pathogenesis. Microbes associated with SCFA production may play a beneficial role in AD treatment, and butyrate supplementation can significantly delay AD progression. pubtype: Academic Journal doctype: diagnostic images pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|